Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Coronary Artery Disease
Interventions: Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon; Device
Lead sponsor: Orchestra BioMed, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 22
States / cities: Phoenix, Arizona • Gainesville, Florida • Hollywood, Florida + 18 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions: Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes; Drug · Radiation · Procedure + 1 more
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 1 Year and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 39
States / cities: Duarte, California • San Francisco, California • Stanford, California + 28 more

Conditions: Depressive Disorder, Major
Interventions: SUVN-911, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • New York, New York + 3 more

Conditions: Achromatopsia
Interventions: Prior exposure to AAV-CNGA3 or AAV-CNGB3; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Solid Tumors
Interventions: PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: New York, New York • Portland, Oregon • Houston, Texas

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Questionnaires, Blood Draw and Baseline Questionnaire; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 1,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Stanford, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Chronic Hepatitis B
Interventions: TDF, Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Covid19
Interventions: Bardoxolone Methyl, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Springfield, Illinois • Brooklyn, New York • Elmhurst, New York + 2 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, triacetyluridine; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 22 more

Conditions: Tennis Elbow
Interventions: TenoMiR, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: Causeway Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Redwood City, California • New York, New York

Conditions: Cancer
Interventions: PFK-158; Drug
Lead sponsor: Advanced Cancer Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Louisville, Kentucky • Houston, Texas + 1 more

Conditions: Bacterial Infection
Interventions: solithromycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: Up to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 31
States / cities: Little Rock, Arkansas • Orange, California • Palo Alto, California + 28 more

Conditions: Diabetic Macular Edema
Interventions: Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter; Drug · Device
Lead sponsor: Oxular Limited; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Bakersfield, California • Minneapolis, Minnesota • Austin, Texas + 2 more

Conditions: Cataracts
Interventions: Lens implantation -1.00 D postop target, Lens implantation 0.00 D postop target; Device
Lead sponsor: Calhoun Vision, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Los Altos, California • Los Angeles, California • Indianapolis, Indiana + 2 more

Conditions: Lip Augmentation
Interventions: New Dermal Filler, Device: FDA Approved Dermal Filler; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years and older
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Encino, California • San Diego, California • Solana Beach, California + 11 more

Conditions: Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions: Prometra II Programmable Pump - Flowonix Medical; Device
Lead sponsor: Culicchia Neurological Clinic; Other
Eligibility: 22 Years to 85 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Marrero, Louisiana

Conditions: Bipolar Depression
Interventions: Lumateperone, Placebo; Drug · Other
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sherman Oaks, California • Miami, Florida + 11 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 79
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Down Syndrome, Intellectual Disability, Alzheimer Dementia (AD)
Interventions: Memantine; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 32 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Osteoarthritis, Knee
Interventions: Atlas(TM) Knee System; Device
Lead sponsor: Moximed; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 9
States / cities: Phoenix, Arizona • Greenwood, Indiana • Boston, Massachusetts + 6 more

Conditions: Friedreich's Ataxia
Interventions: VP 20629, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more

Search by objective public record fields.

Virtue® SAB in the Treatment of Coronary ISR Trial

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Cancer Genetics Hereditary Cancer Panel Testing

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)

New Dermal Filler for Lip Augmentation

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Escalating Doses of Memantine in Down Syndrome (MEDS-123)

Atlas Knee System Clinical System Clinical Study (USA)

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia